ArticleWorld journal of surgical oncology2025
A clinical investigation of extracranial metastases in 17 cases of intracranial solitary fibrous tumors.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Intramedullary solitary fibrous tumor at the C7-T1 level diagnosed by STAT6 and treated with maximal safe resection.Frontiers in surgery · 2026Article
- Robot-assisted laparoscopic prostate-sparing resection of an extremely rare periprostatic solitary fibrous tumor: a case report and literature review.World journal of surgical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the clinical features, pathological progression, and treatment strategies for distant metastases of intracranial solitary fibrous tumors (ISFTs).
methodsA retrospective analysis was conducted on 17 patients with ISFTs and documented distant metastases, treated at a single institution between 2001 and 2023. Disease progression and treatment outcomes were systematically reviewed.
resultsOf the 17 patients, 14 experienced in situ recurrence following resection of the primary intracranial tumor, necessitating a total of 41 intracranial lesion resections. Based on initial pathological assessments, the cases were classified as grade 1 (n = 4), grade 2 (n = 10), and grade 3 (n = 3) ISFTs. Over time, all but one grade 1 and grade 2 tumor were reclassified as grade 3. Following initial resections, 13 patients underwent local radiotherapy and 2 received systemic chemotherapy prior to the development of distant metastases. After metastasis, 8 patients underwent metastatic tumor resection, while 7 received conservative treatment, and 2 did not undergo any intervention. A total of 10 patients, including 2 who withdraw treatment, were followed until the end point. The average survival time for this group was 106 months (range: 23-190 months), with an average survival of 20.89 months (range: 2-60 months) following the diagnosis of distant metastases. Mortality was attributed to functional failure of vital organs, tumor burden, systemic failure, or cachexia. The remaining 7 cases underwent active treatment and are still being monitored. The average total follow-up duration was 145.57 months (range: 95-256 months), while the average follow-up time after distant metastasis diagnosis was 33.42 months (range: 13-72 months).
conclusionSurgical resection remains the primary treatment modality for ISFTs, with adjuvant radiotherapy recommended to delay recurrence. Recurrent tumors frequently exhibit pathological grade progression. Gamma knife radiosurgery is effective for small recurrences, while larger tumors often require repeated surgical resections to manage the primary lesion. The development of distant metastases signifies advanced disease, requiring a multidisciplinary approach that incorporates surgical resection, radiotherapy, and targeted therapies. Distant metastasis remains the primary cause of mortality following active treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.